Costo económico de las bacteriemias causadas por enterobacterias resistentes a carbapenémicos en una institución de Bogotá

Vista sencilla de ítem
dc.contributor.advisorLeal Castro, Aura Luciaspa
dc.contributor.advisorAlvis Zakzuk, Nelson Joséspa
dc.contributor.authorBeltrán Toca, Lina Maríaspa
dc.date.accessioned2020-12-09T17:23:38Zspa
dc.date.available2020-12-09T17:23:38Zspa
dc.date.issued2020-12-08spa
dc.description.abstractBacterial infections with an antibiotical resistance profile are considered a worldwide public health problem. These infections are related to worse clinical outcomes, higher consumption of healthcare resources increasing the length of stays, absenteeism in the workplace and the economic burden that society and health system must bear. A retrospective cost of illness analysis was performed. By means of the technique of micro-costing, the frequencies of use of sanitary resources and the direct medical costs derived from the attention of bacteremia episodes by Enterobacteriaceae with carbapenemic resistance profile were estimated and compared. Additionally, a case-control design was used to estimate the factors associated with cost variation.spa
dc.description.abstractLas infecciones por bacterias con perfil de resistencia a antibióticos son consideradas como un problema de salud pública a nivel mundial. Estas infecciones están relacionadas con peores desenlaces clínicos, mayor consumo de recursos sanitarios, aumento de estancias hospitalarias, ausentismo laboral y una carga económica que la sociedad y el sistema de salud deben soportar. Se realizó un análisis de costo de enfermedad retrospectivo. Mediante la técnica de micro costeo, se estimaron y compararon las frecuencias de uso de recursos sanitarios y los costos directos médicos derivados de la atención de episodios de bacteriemia por Enterobacteriales con perfil de resistencia a carbapenémicos. Adicionalmente, se utilizó un diseño de casos y controles para estimar los factores asociados a la variación de los costos.spa
dc.description.additionalLínea de investigación: Resistencia bacteriana con énfasis en microorganismos intrahospitalariosspa
dc.description.degreelevelMaestríaspa
dc.description.researchareaResistencia bacteriana con énfasis en microorganismos intrahospitalariosspa
dc.format.extent139spa
dc.format.mimetypeapplication/pdfspa
dc.identifier.urihttps://repositorio.unal.edu.co/handle/unal/78690
dc.language.isospaspa
dc.publisher.branchUniversidad Nacional de Colombia - Sede Bogotáspa
dc.publisher.programBogotá - Medicina - Maestría en Infecciones y Salud en el Trópicospa
dc.relation.referencesAngles E. Uso racional de antimicrobianos y resistencia bacteriana ¿hacia dónde vamos? Rev Medica Hered. 2018;29(1):3.spa
dc.relation.referencesAlós J. Resistencia bacteriana a los antibióticos : una crisis global Antibiotic resistance : A global crisis. Enferm Infecc Microbiol Clin. 2015;33(10):692–9spa
dc.relation.referencesWHO. Global priority list of antibiotic-resistant batceria to guide research, discovery, and development of new antibiotics. Who [Internet]. 2017;7. Available from: https://www.who.int/news-room/detail/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-neededspa
dc.relation.referencesSotomayor H, Burgos J, Arango M. Demostración de tuberculosis en una momia prehispanica colombiana por la ribotipificación del ADN de Mycobacterium tuberculosis. Biomédica [Internet]. 2004 [cited 2018 May 8];24:18–26. Available from: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0120-41572004000500004spa
dc.relation.referencesLemos E V. Impacto económico y clínico de la resistencia bacteriana a partir del análisis de Acinetobacter baumannii en unidades de cuidado intensivo de instituciones de tercer nivel de Bogotá. 2010.spa
dc.relation.referencesLemos E V., de la Hoz FP, Alvis N, Quevedo E, Einarson TR, Castañeda C, et al. Infectio : revista de la Asociación Colombiana de Infectología. Infectio [Internet]. 2013;17(4):185–92. Available from: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0123-93922013000400004spa
dc.relation.referencesBarrero LI, Castillo JS, Leal AL, Sánchez R, Cortés JA, Álvarez CA, et al. Impacto económico de la resistencia a meticilina en pacientes con bacteriemia por Staphylococcus aureus en hospitales de Bogotá. Biomédica [Internet]. 2014;34(3):345–53. Available from: http://www.revistabiomedica.org/index.php/biomedica/article/view/1692spa
dc.relation.referencesHernández-gómez C, Motoa G, Pallares C, Muñoz JS, Escandón-vargas K, Álvarez C, et al. Economic Impact of Carbapenemase-Producing Enterobacteriaceae Bloodstream Infection in Latin America. 2015;(October):10–1.spa
dc.relation.referencesVargas-Alzate CA, Higuita-Gutiérrez LF, Jiménez-Quiceno JN. Costos médicos directos de las infecciones del tracto urinario por bacilos Gram negativos resistentes a betalactámicos en un hospital de alta complejidad de Medellín, Colombia. Biomédica. 2019;39:35–49.spa
dc.relation.referencesAngeles-R. MC, Morales-J. AC, Yacarini-M. AE. Resistencia a los antibióticos: Agravamiento en la situación de salud pública. Rev del Cuerpo Médico del HNAAA. 2020;13(1):99–100.spa
dc.relation.referencesPérez DQ. Antimicrobial resistance: Evolution and current perspectives in the context of the “one health” approach. Rev Cubana Med Trop. 2017;69(3):1–17.spa
dc.relation.referencesWHO. Plan De Acción Mundial Sobre La Resistencia a Los Antimicrobianos. WHO Libr Cat Publ daata [Internet]. 2015; Available from: https://apps.who.int/iris/bitstream/handle/10665/255204/9789243509761-spa.pdf?ua=1spa
dc.relation.references(INS) IN de S. Circular 1000 - 0057. Fortalecimiento de las acciones de prevención, vigilancia y control de la emergencia y diseminacion de infecciones por Enterobacterias resistentes a carbapanémicos. 2012; Available from: http://www.ins.gov.co/normatividad/Normatividad/circular 0057 de 2012.PDFspa
dc.relation.referencesInstituto Nacional de Salud (INS). Resultados del Programa de Vigilancia por Laboratorio de Resistencia antimicrobiana en Infecciones Asociadas a la Atención en Salud ( IAAS ) 2016. 2016.spa
dc.relation.referencesCastillo JS, Leal AL, Alvarez CA, Cortés JA, Henríquez DE, Buitrago G, et al. Bacteriemia por Staphylococcus aureus resistente a la meticilina en la unidad de cuidados intensivos: revisión de los estudios de pronóstico. Infectio [Internet]. 2011;15(1):25–32. Available from: http://www.sciencedirect.com/science/article/pii/S012393921170073Xspa
dc.relation.referencesMinisterio de Salud y Protección Social. PLAN NACIONAL DE RESPUESTA A LA RESISTENCIA A ANTIMICROBIANOS. 2018spa
dc.relation.referencesJanet Hindler MA, Humphries RM, Schuetz A, Professor D. CLSI AST News Update. 2020.spa
dc.relation.referencesAdeolu M, Alnajar S, Naushad S, Gupta RS. Genome-based phylogeny and taxonomy of the ‘Enterobacteriales’: Proposal for enterobacterales ord. nov. divided into the families Enterobacteriaceae, Erwiniaceae fam. nov., Pectobacteriaceae fam. nov., Yersiniaceae fam. nov., Hafniaceae fam. nov., Morgane. Int J Syst Evol Microbiol. 2016;66(12):5575–99.spa
dc.relation.referencesJanda JM. The Prokaryotes. In: Dworkin M, Falkow S, Rosenberg E, Schleifer K-H, Stackebrandt E, editors. The Prokaryotes [Internet]. Tercera ed. Springer; 2006. p. 5–40. Available from: http://www.springerlink.com/index/10.1007/0-387-30741-9spa
dc.relation.referencesFam N, Opin C, Comm J, Iii JJF, Control D, Diseases D, et al. Enterobacteriaceae. 2015spa
dc.relation.referencesPatel AK, Singhania RR, Pandey A, Joshi VK, Nigam PS, Soccol CR. Enterobacteriaceae, Coliforms and E.Coli: Introduction. Encycl Food Microbiol Second Ed. 2014;1:659–66.spa
dc.relation.referencesChurch LWP. Enterobacteriaceae. Clin Infect Dis Second Ed. 2015;888–94.spa
dc.relation.referencesDelcour AH. Outer Membrane Permeability and Antibiotic Resistance. Biochim Biophys Acta [Internet]. 2009;1794(5):808–16. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2696358/pdf/nihms114274.pdfspa
dc.relation.referencesVinogradov E, Frirdich E, MacLean LL, Perry MB, Petersen BO, Duus JØ, et al. Structures of lipopolysaccharides from Klebsiella pneumoniae. Eluicidation of the structure of the linkage region between core and polysaccharide O chain and identification of the residues at the non-reducing termini of the O chains. J Biol Chem [Internet]. 2002 Jul 12 [cited 2018 Apr 23];277(28):25070–81. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11986326spa
dc.relation.referencesFarfán-garcía AE, Ariza-rojas SC, Andrea F, Lizeth V, Farfán-garcía AE. Mecanismos de virulencia de Escherichia coli enteropatógena. Rev Chil Infecto. 2016;33(4):438–50.spa
dc.relation.referencesTindall BJ, Sutton G, Garrity GM. Enterobacter aerogenes hormaeche and Edwards 1960 (Approved lists 1980) and Klebsiella mobilis bascomb et al. 1971 (approved lists 1980) share the same nomenclatural type (ATCC 13048) on the approved lists and are homotypic synonyms, with consequences for. Int J Syst Evol Microbiol. 2017;67(2):502–4spa
dc.relation.referencesNom AL, Opin C, Comm J, Grimont PAD, Grimont F, Entérobactéries U, et al. Enterobacter. Bergey’sManual Syst Archaea Bact Online. 2015;spa
dc.relation.referencesPaterson DL. Resistance in gram-negative bacteria: Enterobacteriaceae. Am J Infect Control. 2006;34(5 SUPPL.):20–8.spa
dc.relation.referencesNordmann P, Poirel L. The difficult-to-control spread of carbapenemase producers among Enterobacteriaceae worldwide. Vol. 20, Clinical Microbiology and Infection. 2014.spa
dc.relation.referencesIslas-Muñoz B, Volkow-Fernández P, Ibanes-Gutiérrez C, Villamar-Ramírez A, Vilar-Compte D, Cornejo-Juárez P. Bloodstream infections in cancer patients. Risk factors associated with mortality. Int J Infect Dis [Internet]. 2018 Jun 1 [cited 2018 Aug 5];71:59–64. Available from: https://www-sciencedirect-com.ezproxy.unal.edu.co/science/article/pii/S120197121830081Xspa
dc.relation.referencesVillegas MV, Jiménez A, Esparza G, Appel TM. Carbapenemase-producing Enterobacteriaceae: A diagnostic, epidemiological and therapeutic challenge. Infectio. 2019;23(4):388–98.spa
dc.relation.referencesYi-Wei Tang, Stratton CW. Advanced techniques in diagnostic microbiology [Internet]. 2006. 550 p. Available from: https://link.springer.com/content/pdf/10.1007%2F0-387-32892-0.pdfspa
dc.relation.referencesGarcía MA, Iglesias JCF, Rotaeche AA, Sánchez MS. Bacteriemia, sepsis y shock séptico. Med - Programa Form Médica Contin Acreditado [Internet]. 2018 Apr [cited 2019 Apr 7];12(52):3066–75. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0304541218300623spa
dc.relation.referencesAkova M. Epidemiology of antimicrobial resistance in bloodstream infections. Virulence. 2016;7(3):252–66.spa
dc.relation.referencesDe La Rosa G, León AL, Jaimes F. Epidemiología y pronóstico de pacientes con infección del torrente sanguíneo en 10 hospitales de Colombia. Rev Chil infectología [Internet]. 2016;33(2):141–9. Available from: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-10182016000200003&lng=en&nrm=iso&tlng=enspa
dc.relation.referencesTham J. Extended-Spectrum Beta-Lactamase- Producing Enterobacteriaceae : Epidemiology , Risk Factors , and Duration of Carriage. 2012;0–85.spa
dc.relation.referencesDrawz SM, Bonomo RA. Three decades of ??-lactamase inhibitors. Clin Microbiol Rev. 2010;23(1):160–201.spa
dc.relation.referencesJeon JH, Lee JH, Lee JJ, Park KS, Karim AM, Lee CR, et al. Structural basis for carbapenem-hydrolyzing mechanisms of carbapenemases conferring antibiotic resistance. Vol. 16, International Journal of Molecular Sciences. 2015.spa
dc.relation.referencesMeletis G. Carbapenem resistance: overview of the problem and future perspectives. Ther Adv Infect Dis. 2016;3(1):15–21.spa
dc.relation.referencesCodjoe F, Donkor E. Carbapenem Resistance: A Review. Med Sci. 2017;6(1):1.spa
dc.relation.referencesBedenić B, Plečko V, Sardelić S, Uzunović S, Godič Torkar K. Carbapenemases in gram-negative bacteria: Laboratory detection and clinical significance. Biomed Res Int. 2014;2014.spa
dc.relation.referencesRao S. Carbapenemases. Microrao. 2012. p. 1–12.spa
dc.relation.referencesSilveira MC, Azevedo da Silva R, Faria da Mota F, Catanho M, Jardim R, R Guimarães AC, et al. Systematic Identification and Classification of β-Lactamases Based on Sequence Similarity Criteria: β-Lactamase Annotation. Evol Bioinforma. 2018;14.spa
dc.relation.referencesRao M, Chandrashaker P, Mahale R, Shivappa S, Gowda R, Chitharagi V. Detection of carbapenemase production in Enterobacteriaceae and Pseudomonas species by carbapenemase Nordmannn - Poirel test. J Lab Physicians. 2019;11(2):107–10.spa
dc.relation.referencesLeal AL, Bocanegra R, Mojica IL, Cely JL. Manual de tomas de muestras para el análisis microbiologico. Secr Dist Salud Bogotá, DC. 2015;21.spa
dc.relation.referencesHrabák J, Chudáčková E, Papagiannitsis CC. Detection of carbapenemases in Enterobacteriaceae: A challenge for diagnostic microbiological laboratories. Clin Microbiol Infect. 2014;20(9):839–53.spa
dc.relation.referencesThe Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing CLSI supplement M100S. Clinical and Laboratory Standards Institute, Wayne, PA. 2016. 256 p.spa
dc.relation.referencesSahu C, Jain V, Mishra P, Prasad K. Clinical and laboratory standars institute versus European committee for antimicrobial susceptibility testing guidelines for interpretation of carbapenem antimicrobial susceptibility results for Escherichia coli in urinary tract infection (UTI). J Lab Physicians. 2018;10(3):289–93.spa
dc.relation.referencesNordmann P, Gniadkowski M, Giske CG, Poirel L, Woodford N, Miriagou V, et al. Identification and screening of carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect [Internet]. 2012;18(5):432–8. Available from: http://dx.doi.org/10.1111/j.1469-0691.2012.03815.xspa
dc.relation.referencesNordmann P, Poirel L. Strategies for identification of carbapenemase-producing enterobacteriaceae. J Antimicrob Chemother. 2013;68(3).spa
dc.relation.referencesPark C-E. Clinical Laboratory Aspect of Carbapenem-Resistant Enterobacteriaceae . Korean J Clin Lab Sci. 2020;52(1):18–27.spa
dc.relation.referencesIovleva A, Doi Y. Carbapenem-Resistant Enterobacteriaceae. Clin Lab Med [Internet]. 2017;37(2):303–15. Available from: http://dx.doi.org/10.1016/j.cll.2017.01.005spa
dc.relation.referencesKost K, Yi J, Rogers B, Jerris R. Comparison of clinical methods for detecting carbapenem-resistant Enterobacteriaceae. Pract Lab Med [Internet]. 2017;8(October 2016):18–25. Available from: http://dx.doi.org/10.1016/j.plabm.2017.03.002spa
dc.relation.referencesGarcia S. Resistencia Y Métodos Fenotípicos De Detección Carbapenemases . Resistance Mechanisms and Phenotypic Methods for Detection. 2018;spa
dc.relation.referencesTrepanier P, Mallard K, Meunier D, Pike R, Brown D, Ashby JP, et al. Carbapenemase-producing Enterobacteriaceae in the UK: A national study (EuSCAPE-UK) on prevalence, incidence, laboratory detection methods and infection control measures. J Antimicrob Chemother. 2017;72(2):596–603.spa
dc.relation.referencesMediavilla- C, Valverde-troya M, Microbiología L De, Microbiología UGC De, Infecciosas E, Hospital P. Original breve Evaluación de un ensayo inmunocromatográfico para la detección de carbapenemasa OXA-48. 2017;30(1):45–9.spa
dc.relation.referencesHofko M, Mischnik A, Kaase M, Zimmermann S, Dalpke AH. Detection of carbapenemases by real-time PCR and melt curve analysis on the BD Max system. J Clin Microbiol. 2014;52(5):1701–4.spa
dc.relation.referencesGhebremedhin B, Halstenbach A, Smiljanic M, Kaase M, Ahmad-Nejad P. MALDI-TOF MS based carbapenemase detection from culture isolates and from positive blood culture vials. Ann Clin Microbiol Antimicrob. 2016;15(1):1–6.spa
dc.relation.referencesGarcía P, Allende F, Legarraga P, Huilcaman M, Solari S. Identificación bacteriana basada en el espectro de masas de proteínas: Una nueva mirada a la microbiología del siglo XXI. Rev Chil infectología [Internet]. 2012 Jun [cited 2018 Apr 24];29(3):263–72. Available from: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-10182012000300003&lng=en&nrm=iso&tlng=enspa
dc.relation.referencesBilozor A, Balode A, Chakhunashvili G, Chumachenko T, Egorova S, Ivanova M, et al. Application of Molecular Methods for Carbapenemase Detection. Front Microbiol. 2019;10(August):1–7.spa
dc.relation.referencesGarcía-Betancur JC, Appel TM, Esparza G, Gales AC, Levy-Hara G, Cornistein W, et al. Update on the epidemiology of carbapenemases in Latin America and the Caribbean. Expert Rev Anti Infect Ther [Internet]. 2020;0(0). Available from: https://doi.org/10.1080/14787210.2020.1813023spa
dc.relation.referencesGutiérrez-Gutiérrez B, Salamanca E, de Cueto M, Hsueh PR, Viale P, Paño-Pardo JR, et al. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis. 2017;17(7):726–34.spa
dc.relation.referencesRodríguez-Baño J, Cisneros JM, Gudiol C, Martínez JA. Treatment of infections caused by carbapenemase-producing Enterobacteriaceae. Enferm Infecc Microbiol Clin [Internet]. 2014;32(S4):49–55. Available from: http://dx.doi.org/10.1016/S0213-005X(14)70174-0spa
dc.relation.referencesDaikos GL, Tsaousi S, Tzouvelekis LS, Anyfantis I, Psichogiou M, Argyropoulou A, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: Lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother. 2014;58(4):2322–8.spa
dc.relation.referencesTumbarello M, Trecarichi EM, De Rosa FG, Giannella M, Giacobbe DR, Bassetti M, et al. Infections caused by KPC-producing Klebsiella pneumoniae: Differences in therapy and mortality in a multicentre study. J Antimicrob Chemother. 2015;70(7):2133–43.spa
dc.relation.referencesBulik CC, Nicolau DP. Double-Carbapenem Therapy for Carbapenemase-Producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2011;55(6):3002–4.spa
dc.relation.referencesKaraiskos I, Antoniadou A, Giamarellou H. Combination therapy for extensively-drug resistant gram-negative bacteria. Expert Rev Anti Infect Ther [Internet]. 2017;15(12):1123–40. Available from: https://doi.org/10.1080/14787210.2017.1410434spa
dc.relation.referencesNi W, Han Y, Liu J, Wei C, Zhao J, Cui J, et al. Tigecycline treatment for carbapenem-resistant enterobacteriaceae infections: A systematic review and meta-analysis. Med (United States). 2016;95(11):1–10.spa
dc.relation.referencesCui N, Cai H, Li Z, Lu Y, Wang G, Lu A. Tigecycline-induced coagulopathy: a literature review. Int J Clin Pharm [Internet]. 2019;41(6):1408–13. Available from: https://doi.org/10.1007/s11096-019-00912-5spa
dc.relation.referencesTumbarello M, Losito AR, Giamarellou H. Optimizing therapy in carbapenem-resistant Enterobacteriaceae infections. Curr Opin Infect Dis. 2018;31(6):566–77.spa
dc.relation.referencesRodriguez-Baño J, Gutiérrez-Gutiérrez B, Machuca I, Pascual A. Treatment of Infections Caused by Extended-Spectrum-Beta-. Clin Microbiol Rev. 2018;31(2):1–42.spa
dc.relation.referencesAl-Ghoul WM, Kim MS, Fazal N, Azim AC, Ali A, Amulic B, et al. cr ipt ce pt us cr ipt Ac ce pt us. J Leukoc Biol [Internet]. 2015;13(3):1–10. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1044532315000147%0Ahttp://www.ncbi.nlm.nih.gov/pubmed/15715589%0Ahttp://www.ncbi.nlm.nih.gov/pubmed/19467703%5Cnhttp://ac.els-cdn.com/S0143400409001313/1-s2.0-S0143400409001313-main.pdf?_tid=499806ed760fd88be79spa
dc.relation.referencesMcKinnell J, Connolly L, Pushkin R, Jubb A, O´Keeffe B, Serio A, et al. Improved Outcomes with Plazomicin (PLZ) Compared with Colistin (CST) in Patients with Bloodstream Infections (BSI) Caused by Carbapenem-resistant Enterobacteriaceae (CRE): Results from the CARE Study. 2017;4(Suppl 1):348–9.spa
dc.relation.referencesCloutier D, Komirenko A, Cebrik D, Keepers T, Krause K, Connolly L, et al. Plazomicin Vs. Meropenem for Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP): Diagnosis-specific Results From the Phase 3 EPIC Study. Vol. 4. 2017.spa
dc.relation.referencesBonomo RA, Bonomo RA. Clinical Infectious Diseases Cefiderocol: A Novel Siderophore Cephalosporin Defeating Carbapenem-resistant Pathogens. Available from: https://ecdc.spa
dc.relation.referencesChew KL, Tay MKL, Cheng B, Lin RTP, Octavia S. Aztreonam - avibactam combinatio restores susceptibility of aztreonam in dual carbapenemase producing Enterobacteriaceae. 2018;62(8):1–3.spa
dc.relation.referencesKattan R, Liddawi R, Ghneim R, Siryani I, Al-dawodi R, Abu-diab A, et al. Emergence of Klebsiella pneumoniae Carbapenemase ( bla KPC-2 ) in members of the Enterobacteriaceae family in Palestine. 2012;2(2):1–9.spa
dc.relation.referencesLogan LK, Weinstein RA. The epidemiology of Carbapenem-resistant enterobacteriaceae: The impact and evolution of a global menace. J Infect Dis. 2017;215(Suppl 1):S28–36.spa
dc.relation.referencesMunoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis [Internet]. 2013;13(9):785–96. Available from: http://dx.doi.org/10.1016/S1473-3099(13)70190-7spa
dc.relation.referencesOcampo AM, Vargas CA, Sierra PM, Cienfuegos AV, Jiménez JN. Caracterización molecular de un brote de Klebsiella pneumoniae resistente a carbapenémicos en un hospital de alto nivel de complejidad de Medellín, Colombia. Biomédica [Internet]. 2015;35(4):496–504. Available from: http://www.revistabiomedica.org/index.php/biomedica/article/view/2610spa
dc.relation.referencesLucía M, Martínez O, Enrique M, Duran M, Vigilancia D, Del Riesgo En A, et al. Protocolo de vigilancia en salud pública infecciones asociadas a dispositivos. Inst Nac Salud [Internet]. 2016;1–65. Available from: http://www.ins.gov.co/lineas-de-accion/Subdireccion-Vigilancia/sivigila/Protocolos SIVIGILA/PRO Infecciones asociadas a dispositivos.pdfspa
dc.relation.referencesEsparza G. Bacterias Gram negativas resistentes a carbapenemicos en Colombia: a desafio continuo al sistema de salud.spa
dc.relation.referencesINS. Informe De Resultados De La Vigilancia Por Laboratorio De Resistencia Antimicrobiana En Infecciones Asociadas a La Atención En Salud (Iaas) 2018 Dirección. Epidemiol las Infecc Asoc a la atención en salud. 2019;29–44.spa
dc.relation.referencesSegel JE. Cost-of-Illness Studies — A Primer. Diabetes [Internet]. 2006;(January):1–39. Available from: http://www.rti.org/pubs/coi_primer.pdfspa
dc.relation.referencesJo C. Cost-of-illness studies: concepts, scopes, and methods. Clin Mol Hepatol [Internet]. 2014 Dec [cited 2018 Apr 24];20(4):327. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25548737spa
dc.relation.referencesMejia Mejia A, Viscaya MM. Evaluación económica para la toma de decisiones en salud en Colombia. Políticas en salud Monit estrátegico [Internet]. 2014;(5):70–5. Available from: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/IA/SSA/Articulo 9.pdfspa
dc.relation.referencesTarricone R. Cost-of-illness analysis. What room in health economics? Health Policy (New York). 2006;77(1):51–63.spa
dc.relation.referencesAndronis L, Barton P, Bryan S. Sensitivity analysis in economic evaluation: An audit of NICE current practice and a review of its use and value in decision-making. Health Technol Assess (Rockv). 2009;13(29).spa
dc.relation.referencesGandra S, Barter DM, Laxminarayan R. Economic burden of antibiotic resistance: how much do we really know? Clin Microbiol Infect [Internet]. 2014;20(10):973–80. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1198743X14653635spa
dc.relation.referencesMejía,Carlos. Villatoro,Guillermo. Silvestre,Mónica. de Britz,Hilda. Valle, Rosa. Remei M. Costo del tratamiento de infecciones nosocomiales por gérmenes multirresistentes, Hospital Roosevelt. Rev Panam Infectol [Internet]. 2008;10(4):96–100. Available from: http://www.revistaapi.com/wp-content/uploads/2014/03/mat-14.pdfspa
dc.relation.referencesHuebner C, Roggelin M, Flessa S. Economic burden of multidrug-resistant bacteria in nursing homes in Germany: a cost analysis based on empirical data. BMJ Open [Internet]. 2016;6(2):e008458. Available from: http://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2015-008458spa
dc.relation.referencesChandy SJ, Naik GS, Balaji V, Jeyaseelan V, Thomas K, Lundborg CS. High cost burden and health consequences of antibiotic resistance: The price to pay. J Infect Dev Ctries. 2014;8(9):1096–102.spa
dc.relation.referencesEvans HL, Lefrak SN, Lyman J, Smith RL, Chong TW, McElearney ST, et al. Cost of Gram-negative resistance*. Crit Care Med [Internet]. 2007;35(1):89–95. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00003246-200701000-00015spa
dc.relation.referencesNg E, Earnest A, Lye DC, Ling ML, Ding Y, Hsu LY. The excess financial burden of multidrug resistance in severe gram-negative infections in Singaporean hospitals. Ann Acad Med Singapore. 2012;41(5):189–93.spa
dc.relation.referencesMacvane SH, Tuttle LO, Nicolau DP. Impact of extended-spectrum ??-lactamase-producing organisms on clinical and economic outcomes in patients with urinary tract infection. J Hosp Med. 2014;9(4):232–8.spa
dc.relation.referencesEsteve-Palau E, Solande G, Sánchez F, Sorlí L, Montero M, Güerri R, et al. Clinical and economic impact of urinary tract infections caused by ESBL-producing Escherichia coli requiring hospitalization: A matched cohort study. J Infect [Internet]. 2015 Dec 1 [cited 2018 Apr 23];71(6):667–74. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0163445315002662spa
dc.relation.referencesMaslikowska JA, Walker SAN, Elligsen M, Mittmann N, Palmay L, Daneman N, et al. Impact of infection with extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella species on outcome and hospitalization costs. J Hosp Infect [Internet]. 2016 Jan [cited 2018 Apr 23];92(1):33–41. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26597637spa
dc.relation.referencesDaroukh A, Delaunay C, Bigot S, Ceci JM, Siddhoun N, Bukreyeva I, et al. Characteristics and costs of carbapenemase-producing enterobacteria carriers (2012/2013). Med Mal Infect [Internet]. 2014;44(7):321–6. Available from: http://dx.doi.org/10.1016/j.medmal.2014.06.004spa
dc.relation.referencesOtter JA, Burgess P, Davies F, Mookerjee S, Singleton J, Gilchrist M, et al. Counting the cost of an outbreak of carbapenemase-producing Enterobacteriaceae: an economic evaluation from a hospital perspective. Clin Microbiol Infect. 2017;23(3):188–96.spa
dc.relation.referencesMeng X, Liu S, Duan J, Huang X, Zhou P, Xiong X, et al. Risk factors and medical costs for healthcare-associated carbapenem-resistant Escherichia coli infection among hospitalized patients in a Chinese teaching hospital. BMC Infect Dis [Internet]. 2017;17(1):82. Available from: http://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-016-2176-9spa
dc.relation.referencesNdir A, Diop A, Ka R, Faye PM, Dia-Badiane NM, Ndoye B, et al. Infections caused by extended-spectrum beta-lactamases producing Enterobacteriaceae: Clinical and economic impact in patients hospitalized in 2 teaching hospitals in Dakar, Senegal. Antimicrob Resist Infect Control [Internet]. 2016;5(1):1–8. Available from: http://dx.doi.org/10.1186/s13756-016-0114-7spa
dc.relation.referencesThaden JT, Pogue JM, Kaye KS. Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae. Virulence. 2017;8(4):403–16.spa
dc.relation.referencesBartsch SM, McKinnell JA, Mueller LE, Miller LG, Gohil SK, Huang SS, et al. Potential economic burden of carbapenem-resistant Enterobacteriaceae (CRE) in the United States. Clin Microbiol Infect [Internet]. 2017;23(1):48.e9-48.e16. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27642178%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC5547745spa
dc.relation.referencesDrummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford university press; 2015.spa
dc.relation.referencesCorporación Hospitalaria Juan Ciudad – Méderi , Colombia Gloria Pulido Moya La Corporación Hospitalaria Juan Ciudad - Méderi.spa
dc.relation.referencesMoreno Viscaya M, Mejía Mejía A, Castro Jaramillo HE. Manual para la elaboración de evaluaciones económicas en salud. Instituto de Evaluación Tecnológia en Salud. 2014.spa
dc.relation.referencesMinisterio de Salud y Protección Social. Listado de precios promedio y unidades en la cadena de comercialización de medicamentos 2018. (Modificado) [Internet]. 2018. Available from: https://web.sispro.gov.co/WebPublico/Consultas/ConsultarCNPMCadenaComercializacionCircu2yPA_028_2_1.aspxspa
dc.relation.referencesFondo Nacional de Estupefacientes. Precio medicamentos de estupefacientes. 2018.spa
dc.relation.referencesMinisterio de Salud y Protección Social. Base de datos de medicamentos con precio regulado o con precio de referencia [Internet]. 2018. Available from: https://www.minsalud.gov.co/salud/MT/Paginas/medicamentos-regulacion-precios.aspxspa
dc.relation.referencesPresidencia de la República. Acuerdo No. 256 DE 2001 Por el cual se aprueba el “Manual de Tarifas” de la Entidad Promotora de Salud del Seguro Social EPS-ISS. Vol. 001. 2001. p. 1–213.spa
dc.relation.referencesAlvis-Zakzuk NJ, Díaz-Jiménez D, Castillo-Rodríguez L, Castañeda-Orjuela C, Paternina-Caicedo Á, Pinzón-Redondo H, et al. Economic Costs of Chikungunya Virus in Colombia. Value Heal Reg Issues. 2018;17(51):32–7.spa
dc.relation.referencesOrtiz-Mayorga JL, Pineda-Rodríguez IG, Dennis RJ, Porras A. Costos atribuidos a las infecciones asociadas con la atención en salud en un hospital de Colombia, 2011-2015. Biomédica [Internet]. 2019;39(1):102–12. Available from: https://www.revistabiomedica.org/index.php/biomedica/article/view/4061spa
dc.relation.referencesGonzalez M del R. Manual de estadistica no parametrica con STATA y STATISTICA. 2000.spa
dc.relation.referencesMinisterio de Salud. Resolución No. 8430 de 1993. Norma científica, técnicas y administrativas para la investigación en salud. 1993;spa
dc.relation.referencesColombia C de la R de. Ley Estaturatia 1581 del 2012. Ámbito De Aplicación. 2018;2012(Octubre 17):1–32.spa
dc.relation.referencesGarcés D, Barragán FJ. Ronda clínica y epidemiológica. Introducción al análisis multivariable (parte II). Iatreia. 2014;28(1):87–96.spa
dc.relation.referencesCastellanos-olivares A, Rojas-peñaloza DJ, Vásquez-márquez DPI. O Causalidad En Medicina ? 2016;232–6.spa
dc.relation.referencesBerea-Baltierra R, Rivas-Ruiz R, Pérez-Rodríguez M, Palacios-Cruz L, Moreno J, Talavera JO. Clinical research XX. From clinical judgment to multiple logistic regression model. Rev Med Inst Mex Seguro Soc. 2014;52(2):192–7.spa
dc.relation.referencesMartinez HC. Impacto economico de la colonizacion nasal por Staphylococcus aureus Meticilino Resistente (SAMR), en pacientes que ingresan al Servicio de Cirugia Cardiovascular del Hospital Universitario San Ignacio (HUSI), de la ciudad de Bogota. 2015spa
dc.relation.referencesHuang W, Qiao F, Zhang Y, Huang J, Deng Y, Li J, et al. In-hospital Medical Costs of Infections Caused by Carbapenem-resistant Klebsiella pneumoniae. Clin Infect Dis. 2018;67(December 2017):S225–30.spa
dc.relation.referencesThaden J, Li Y, Ruffin F, Maskarenic S, Hill-Rorie JM, Wanda L, et al. Increased cost with multidrug resistant gram Negative bloodstream infections are primarily due to patients with hospital acquired infections. Antimicrob Agents Chemoterapy. 2016;(December):1–27.spa
dc.relation.referencesJudd WR, Ratliff PD, Hickson RP, Stephens DM, Kennedy CA. Clinical and economic impact of meropenem resistance in Pseudomonas aeruginosa–infected patients. Am J Infect Control [Internet]. 2016;44(11):1275–9. Available from: http://dx.doi.org/10.1016/j.ajic.2016.04.218spa
dc.relation.referencesUlu kılıc ayşegül. Economic burden of multidrug resistant gram negative infections in a developing country. Erciyes Med J. 2019;41(3):2017–20.spa
dc.relation.referencesSegagni Lusignani L, Presterl E, Zatorska B, Van den Nest M, Diab-Elschahawi M. Infection control and risk factors for acquisition of carbapenemase-producing enterobacteriaceae. A 5 year (2011-2016) case-control study. Antimicrob Resist Infect Control [Internet]. 2020 Jan 17;9:18. Available from: https://pubmed.ncbi.nlm.nih.gov/31988746spa
dc.relation.referencesSt JH. Code sepsis initiatives. In: American Journal of Nursing. 2018. p. 130.spa
dc.relation.referencesSunny T, Jacob R, K K, Varghese S. Self-medication: Is a serious challenge to control antibiotic resistance? Natl J Physiol Pharm Pharmacol. 2019;9(0):1.spa
dc.relation.referencesManyi-Loh C, Mamphweli S, Meyer E, Okoh A. Antibiotic Use in Agriculture and Its Consequential Resistance in Environmental Sources: Potential Public Health Implications. Molecules [Internet]. 2018 Mar 30;23(4):795. Available from: https://pubmed.ncbi.nlm.nih.gov/29601469spa
dc.relation.referencesServices U. D of H and H. Antibiotic resistance threats in the United States. Centers Dis Control Prev [Internet]. 2019;1–113. Available from: https://www.cdc.gov/drugresistance/biggest_threats.htmlspa
dc.relation.referencesJaime Cerda L. Glosario de términos utilizados en evaluación económica de la salud. Rev Med Chil [Internet]. 2010 Sep [cited 2020 Oct 9];138(SUPPL. 2):76–8. Available from: https://scielo.conicyt.cl/scielo.php?script=sci_arttext&pid=S0034-98872010001000003&lng=es&nrm=iso&tlng=esspa
dc.relation.referencesGrau S. Principales variables que determinan el coste económico en el tratamiento de una infección. Enferm Infecc Microbiol Clin [Internet]. 2017;35(Supl 1):41–5. Available from: http://dx.doi.org/10.1016/S0213-005X(17)30035-6spa
dc.relation.referencesMauldin PD, Salgado CD, Hansen IS, Durup DT, Bosso JA. Attributable hospital cost and length of stay associated with health care-associated infections caused by antibiotic-resistant gram-negative bacteria. Antimicrob Agents Chemother. 2010;54(1):109–15.spa
dc.relation.referencesMariappan S, Sekar U, Kamalanathan A. Carbapenemase-producing Enterobacteriaceae: Risk factors for infection and impact of resistance on outcomes. Int J Appl basic Med Res [Internet]. 2017;7Mariappan(1):32–9. Available from: https://pubmed.ncbi.nlm.nih.gov/28251105spa
dc.relation.referencesGualtero S, Valderrama S, Valencia M, Rueda D, Muñoz-Velandia O, Ariza B, et al. Factors associated with mortality in Infections caused by Carbapenem-resistant Enterobacteriaceae. J Infect Dev Ctries. 2020;14(6):654–9.spa
dc.rightsDerechos reservados - Universidad Nacional de Colombiaspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.licenseAtribución-NoComercial 4.0 Internacionalspa
dc.rights.spaAcceso abiertospa
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/spa
dc.subject.proposalCost of illnesseng
dc.subject.proposalCostos de la enfermedadspa
dc.subject.proposalDrug resistanceeng
dc.subject.proposalResistencia a antibióticosspa
dc.subject.proposalBacteremiaeng
dc.subject.proposalBacteriemiasspa
dc.subject.proposalEnterobacteriaceae resistente a carbapenémicosspa
dc.subject.proposalCarbapenem - resistant Enterobacteriaceaeeng
dc.titleCosto económico de las bacteriemias causadas por enterobacterias resistentes a carbapenémicos en una institución de Bogotáspa
dc.typeTrabajo de grado - Maestríaspa
dc.type.coarhttp://purl.org/coar/resource_type/c_bdccspa
dc.type.coarversionhttp://purl.org/coar/version/c_ab4af688f83e57aaspa
dc.type.contentTextspa
dc.type.driverinfo:eu-repo/semantics/masterThesisspa
dc.type.versioninfo:eu-repo/semantics/acceptedVersionspa
oaire.accessrightshttp://purl.org/coar/access_right/c_abf2spa

Archivos

Bloque original

Mostrando 1 - 1 de 1
Miniatura
Nombre:
1019068120.2020.pdf
Tamaño:
1.67 MB
Formato:
Adobe Portable Document Format
Descargar

Bloque de licencias

Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
3.8 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Maestría en Infecciones y Salud en el Trópico